US6548547B1 - Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators - Google Patents

Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators Download PDF

Info

Publication number
US6548547B1
US6548547B1 US09/743,199 US74319901A US6548547B1 US 6548547 B1 US6548547 B1 US 6548547B1 US 74319901 A US74319901 A US 74319901A US 6548547 B1 US6548547 B1 US 6548547B1
Authority
US
United States
Prior art keywords
alkyl
aryl
radicals
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/743,199
Other languages
English (en)
Inventor
Ursula Schindler
Karl Schoenafinger
Hartmut Strobel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Assigned to AVENTIS PHARMA DEUTSCHLAND GMBH reassignment AVENTIS PHARMA DEUTSCHLAND GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHINDLER, URSULA, SCHOENAFINGER, KARL, STROBEL, HARTMUT
Priority to US10/349,907 priority Critical patent/US6809089B2/en
Application granted granted Critical
Publication of US6548547B1 publication Critical patent/US6548547B1/en
Priority to US10/957,980 priority patent/US7351703B2/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids

Definitions

  • the present invention relates to compounds of the formula I
  • a 1 , A 2 , R 2 and R 3 have the meanings indicated below, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis.
  • the compounds of the formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance.
  • the invention relates to the use of compounds of the formula I for the therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, novel compounds of the formula I, pharmaceutical preparations comprising them and processes for their preparation.
  • cGMP is an important intracellular messenger, which elicits a number of pharmacological effects by means of the modulation of cGMP-dependent protein kinases, phosphodiesterases and ion channels. Examples are smooth muscle relaxation, the inhibition of platelet activation and the inhibition of smooth muscle cell proliferation and leukocyte adhesion.
  • cGMP is produced by particulate and soluble guanylate cyclases as a response to a number of extracellular and intracellular stimuli. In the case of the particulate guanylate cyclases, the stimulation essentially takes place by means of peptidic messenger substances, such as the atrial natriuretic peptide or the cerebral natriuretic peptide.
  • sGC soluble guanylate cyclases
  • the most important stimulant is nitrogen monoxide (NO) or a closely relates species.
  • NO nitrogen monoxide
  • the importance of other factors such as carbon monoxide or the hydroxyl radical is still largely unclarified.
  • NO nitrogen monoxide
  • the binding of NO to the heme with formation of a pentacoordinated heme-nitrosyl complex is discussed as an activation mechanism of activation by NO.
  • the release associated therewith of the histidine which is bound to the iron in the basal state converts the enzyme into the activated conformation.
  • Active soluble guanylate cyclases are each composed of one ⁇ - and one ⁇ -subunit.
  • Several subtypes of the subunits have been described, which differ from one another with respect to sequence, tissue-specific distribution and expression in various stages of development.
  • the subtypes ⁇ 1 and ⁇ 1 are mainly expressed in the brain and lung, while ⁇ 2 is especially found in liver and kidney.
  • the subtype ⁇ 2 was detected in human fetal brain.
  • the subunits designated as ⁇ 3 and ⁇ 3 were isolated from human brain and are homologous to ⁇ 1 and ⁇ 1 .
  • More recent studies point to an ⁇ 2i subunit, which contains an insert in the catalytic domain. All subunits show great homology in the area of the catalytic domain.
  • the enzymes presumably contain one heme per heterodimer, which is bonded via ⁇ 1 -Cys-78 and/or ⁇ 1 -His-105 and is part of the regulatory center.
  • guanylate cyclase-activating factors can be decreased under pathological conditions or increased degradation thereof can take place as a result of the increased occurrence of free radicals.
  • the decreased activation of the sGC resulting therefrom leads, via the attenuation of the respective cGMP-mediated cell response, for example, to an increase in the blood pressure, to platelet activation or to increased cell proliferation and cell adhesion.
  • the formation of endothelial dysfunction, atherosclerosis, high blood pressure, stable and unstable angina pectoris, thromboses, myocardial infarct, strokes or erectile dysfunction occurs.
  • the pharmacological stimulation of the sGC offers a possibility for the normalization of cGMP production and thus allows the treatment or prevention of diseases of this type.
  • Pettibone et al. (Eur. J. Pharmacol. 116 (1985) 307) described a hypotensive action for diphenyliodonium hexafluorophosphate and attributed this to a stimulation of sGC.
  • Isoliquiritiginin which shows a relaxant action on isolated rat aortas, likewise activates sGC according to Yu et al. (Brit. J. Pharmacol. 114 (1995) 1587).
  • a number of sulfonylaminocarboxylic acid N-arylamides of the formula I are already known. Compounds of this type are used, for example, in the production of photographic materials (see, for example, Chemical Abstracts 119, 105 755; 116, 245 151 and 104, 177 628) and, for this purpose, then in general contain in the N-aryl group as substituents easily oxidizable groups such as, for example, two hydroxyl groups in the para-position to one another. For various compounds of the formula I, a pharmacological action has also already been described.
  • certain compounds of the formula I having a phenyl pivalate structure are elastase inhibitors and can be used in the treatment of atherosclerosis or arthritis.
  • Chemical Abstracts 104, 33 896 a psychotropic action is described for certain 2-sulfonylaminobenzoic acid N-phenoxyphenylamides.
  • Various 2-trifluoromethylsulfonylamino- and 2-methylsulfonylamino-substituted benzamides are described as angiotensin II receptor antagonists having antihypertensive activity in Hypertension 15 (1998) 823, J. Med. Chem. 33 (1990) 1312, EP-A-253 310, EP-A-324 377, EP-A-449 699, EP-A-530 702 and U.S. Pat. No. 4,880,804.
  • the present invention thus relates to the use of compounds of the formula I
  • a 1 is a radical from the group consisting of phenyl, naphthyl and heteroaryl, which can all be substituted by one or more identical or different radicals R 1 ;
  • the ring A 2 which includes the carbon atoms which carry the groups CO—NH— and NH—SO 2 R 2 , is a benzene ring, a naphthalene ring, a saturated or partially unsaturated 3-membered to 7-membered carbocycle, a saturated, partially unsaturated or aromatic monocyclic 5-membered to 7-membered heterocycle which contains one or more ring heteroatoms from the group consisting of N, O and S, or a saturated, partially unsaturated or aromatic bicyclic 8-membered to 10-membered heterocycle which contains one or more ring heteroatoms from the group consisting of N, O and S;
  • R 1 is halogen, aryl, CF 3 , NO 2 , OH, —O—(C 1 -C 7 )-alkyl, —O—(C 2 -C 4 )-alkyl—O—(C 1 -C 7 )-alkyl, —O-aryl, (C 1 -C 2 )-alkylenedioxy, NR 5 R 6 , CN, CO—NR 5 R 6 , COOH, CO—O—(C 1 -C 5 )-alkyl, heterocyclyl, CHO, CO—(C 1 -C 10 )-alkyl, CO-aryl or (C 1 -C 10 )-alkyl which can be substituted by one or more identical or different radicals R 4 ;
  • R 2 is aryl, heterocyclyl, NR 5 R 6 or (C 1 -C 10 )-alkyl which can be substituted by one or more identical or different radicals R 4 ;
  • R 3 is one or more identical or different substituents from the group consisting of hydrogen, halogen, CF 3 , OH, —O—(C 1 -C 10 )-alkyl, —O—(C 1 -C 7 )-alkyl-R 7 , —O-aryl, SH, —S—(C 1 -C 10 )-alkyl, —S—(C 1 -C 7 )-alkyl-R 7 , —S-aryl, (C 1 -C 3 )-alkylenedioxy, CN, NO 2 , NR 8 R 9 , CO—NR 5 R 6 , COOH, CO—O—(C 1 -C 5 )-alkyl, heterocyclyl, S(O) n —(C 1 -C 7 )-alkyl, S(O) n -aryl, S(O) n —NR 5 R 6 and (C 1 -C 7 )-alkyl which can
  • R 4 is fluorine, OH, —O—(C 1 -C 10 )-alkyl, —O—(C 1 -C 7 )-alkyl-R 7 , —O-aryl, SH, —S—(C 1 -C 10 )-alkyl, —S—(C 1 -C 7 )-alkyl-R 7 , —S-aryl, —P(O)(O—(C 1 -C 5 )-alkyl) 2 , —P(O)(OH) 2 , CN, NR 8 R 9 , CO—NH 2 , CO—NH—(C 1 -C 3 )-alkyl, CO—N((C 1 -C 3 )-alkyl) 2 , COOH, CO—O—(C 1 -C 5 )-alkyl, heterocyclyl or oxo;
  • R 5 is hydrogen, (C 1 -C 10 )-alkyl which can be substituted by one or more identical or different substituents R 4 and/or by aryl, or is aryl, heterocyclyl, CO—(C 1 -C 10 )-alkyl, CO-aryl, CO-heterocyclyl, SO 2 —(C 1 -C 10 )-alkyl, SO 2 -aryl or SO 2 -heterocyclyl;
  • R 6 independently of R 5 , has one of the meanings indicated for R 5 , or R 5 and R 6 , together with the nitrogen atom to which they are bonded, form a 5-membered to 8-membered saturated or partially unsaturated ring which, in addition to the nitrogen atom carrying the groups R 5 and R 6 , can also contain one or more further ring heteroatoms from the group consisting of N, O and S and which can be substituted by one or more identical or different substituents from the group consisting of fluorine, (C 1 -C 5 )-alkyl, (C 1 -C 3 )-hydroxyalkyl, —(C 1 -C 3 )-alkyl-O—(C 1 -C 4 )-alkyl, aryl, CF 3 , OH, —O—(C 1 -C 7 )-alkyl, —O-aryl, —O—(C 2 -C 4 )-alkyl—O—(C 1 -
  • R 7 is OH, —O—(C 1 -C 7 )-alkyl, NH 2 , —NH—(C 1 -C 4 )-alkyl or —N((C 1 -C 4 )-alkyl) 2 , where in the substituent N((C 1 -C 4 )-alkyl) 2 the two alkyl groups can be linked by a single bond and then, together with the nitrogen atom carrying them, form a 5-membered to 7-membered ring which, in addition to the nitrogen atom and the carbon atoms can additionally also contain an oxygen atom, a sulfur atom or a group NR 5 as a ring member;
  • R 8 is hydrogen or (C 1 -C 7 )-alkyl which can be substituted by one or more identical or different substituents from the group consisting of OH, —O—(C 1 -C 5 )-alkyl, NH 2 , —NH—(C 1 -C 4 )-alkyl and —N((C 1 -C 4 )-alkyl) 2 ;
  • R 9 independently of R 8 , has one of the meanings of R 8 or is CO—(C 1 -C 4 )-alkyl;
  • aryl is phenyl, naphthyl or heteroaryl, which can all be substituted by one or more identical or different substituents from the group consisting of halogen, (C 1 -C 5 )-alkyl, phenyl, tolyl, CF 3 , NO 2 , OH, —O—(C 1 -C 5 )-alkyl, —O—(C 2 -C 4 )-alkyl-O—(C 1 -C 3 )-alkyl, (C 1 -C 2 )-alkylenedioxy, NH 2 , —NH—(C 1 -C 3 )-alkyl, —N((C 1 -C 3 )-alkyl) 2 , NH—CHO, —NH—CO—(C 1 -C 5 )-alkyl, CN, CO—NH 2 , CO—NH—(C 1 -C 3 )-alkyl, CO—N((C 1 -
  • heteroaryl is the radical of a monocyclic 5-membered or 6-membered aromatic heterocycle or of a bicyclic 8-membered to 10-membered aromatic heterocycle, each of which contain one or more ring heteroatoms from the group consisting of N, O and S;
  • heterocyclyl is the radical of a monocyclic or polycyclic, 5-membered to 11-membered saturated or partially unsaturated heterocycle which contains one or more ring heteroatoms from the group consisting of N, O and S and which can be substituted by one or more identical or different substituents from the group consisting of fluorine, (C 1 -C 5 )-alkyl, OH, —O—(C 1 -C 5 )-alkyl, —O—(C 2 -C 4 )-alkyl-O—(C 1 -C 3 )-alkyl, NH 2 , —NH—(C 1 -C 3 )-alkyl, —N((C 1
  • n 0, 1 or 2;
  • n 2, 3 or 4;
  • Alkyl radicals can be straight-chain or branched. This also applies if they are contained in other groups, for example in alkoxy groups, alkoxycarbonyl groups or in amino groups, or if they are substituted. Examples of alkyl groups are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, the n-isomers of these radicals, isopropyl, isobutyl, isopentyl, sec-butyl, tert-butyl, neopentyl, 3,3-dimethylbutyl.
  • alkyl here is expressly also understood as meaning unsaturated alkyl radicals, i.e. alkyl radicals which contain one or more double bonds and/or one or more triple bonds, i.e. alkenyl radicals and alkynyl radicals.
  • alkyl radicals which contain one or more double bonds and/or one or more triple bonds, i.e. alkenyl radicals and alkynyl radicals.
  • examples of such radicals are the vinyl radical, the 2-propenyl radical (allyl radical), the 2-butenyl radical, the 2-methyl-2-propenyl radical, the ethynyl radical, the 2-propynyl radical (propargyl radical) or the 3-butynyl radical.
  • alkyl here is expressly also understood as meaning radicals in which a cyclic system is formed by means of an internal ring closure, i.
  • alkyl also includes saturated and partially unsaturated cycloalkyl radicals and cydoalkylalkyl radicals (alkyl substituted by cycloalkyl).
  • cycloalkyl radicals are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which all can also be substituted, for example, by one or more identical or different (C 1 -C 4 )-alkyl radicals, in particular by methyl.
  • alkyl examples include 4-methylcyclohexyl, 4-tert-butylcyclohexyl or 2,3-dimethylcyclopentyl.
  • alkyl if not stated otherwise, here expressly also includes both unsubstituted alkyl radicals and alkyl radicals which are substituted by one or more, for example one, two, three or four, identical or different aryl radicals. I.e., the term alkyl here is expressly also understood as meaning arylalkyl radicals, for example benzyl radicals, phenylethyl radicals or indanyl radicals.
  • a saturated or partially unsaturated 3-membered to 7-membered carbocycle representing the ring A 2 can be derived from the monocyclic parent structures cyclopropane, cydobutane, cyclopentane, cyclohexane or cycloheptane. If the carbocycle is unsaturated, it can contain, for example, a double bond or, in the case of the 5-membered ring, 6-membered ring or 7-membered ring, also two double bonds, which can be isolated or conjugated. Double bonds can be situated in any desired positions with respect to the groups CO—NH— and NH—SO 2 -R 2 , thus, for example, a double bond can also be situated between the two ring carbon atoms which carry these two groups.
  • phenyl radicals, phenoxy radicals, benzyl radicals or benzyloxy radicals are present in aryl radicals such as, for example, phenyl radicals and/or in heterocyclic radicals as substituents
  • the benzene ring in these can also in turn be unsubstituted or can be substituted by one or more, for example one, two, three or four, identical or different radicals, for example by radicals from the group consisting of (C 1 -C 4 )-alkyl, halogen, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethyl, cyano, hydroxycarbonyl, ((C 1 -C 4 )-alkoxy)carbonyl, aminocarbonyl, nitro, amino, (C 1 -C 4 )-alkylamino, di-((C 1 -C 4 )-alkyl)amino and ((C 1 -C 4 )-alkyl
  • the substituent in monosubstituted phenyl radicals, can be situated in the 2-position, the 3-position or the 4-position, in disubstituted phenyl radicals the substituents can be situated in the 2,3-position, 2,4-position, 2,5-position, 2,6-position, 3,4-position or 3,5-position. In trisubstituted phenyl radicals, the substituents can be situated in the 2,3,4-position, 2,3,5-position, 2,3,6-position, 2,4,5-position, 2,4,6-position or 3,4,5-position.
  • Naphthyl can be 1-naphthyl or 2-naphthyl.
  • the substituent in monosubstituted 1-naphthyl radicals, can be situated in the 2-position, the 3-position, the 4-position, the 5-position, the 6-position, the 7-position or the 8-position, in monosubstituted 2-naphthyl radicals in the 1-position, the 3-position, the 4-position, the 5-position, the 6-position, the 7-position or the 8-position.
  • the substituents can also be situated in all possible positions.
  • Heteroaryl radicals, heterocyclyl radicals, heterocycles representing the ring A 2 and rings which are formed from two groups bonded to a nitrogen atom together with this nitrogen atom are preferably derived from heterocycles which contain one, two, three or four identical or different ring heteroatoms, particularly preferably from heterocycles which contain one or two or three, in particular one or two, identical or different heteroatoms.
  • the heterocycles can be monocyclic or polycyclic, for example monocyclic, bicyclic or tricyclic. They are preferably monocyclic or bicyclic.
  • the rings are preferably 5-membered rings, 6-membered rings or 7-membered rings.
  • Examples of monocyclic and bicyclic heterocyclic systems from which radicals occurring in the compounds of the formula I can be derived are pyrrole, furan, thiophene, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, 1,3-dioxole, 1,3-oxazole, 1,2-oxazole, 1,3-thiazole, 1,2-thiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, pyran, thiopyran, 1,4-dioxin, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,4,5-tetrazine, azepine, 1,2-diaze
  • the suitable heterocycles thus also include, for example, the saturated heterocycles pyrrolidine, piperidine, piperazine, morpholine and thiomorpholine.
  • the degree of saturation of heterocyclic groups is indicated in the individual definitions.
  • Unsaturated heterocycles can contain, for example, one, two or three double bonds in the ring system.
  • 5-Membered rings and 6-membered rings in monocyclic and polycyclic heterocycles can in particular also be aromatic.
  • the radicals derived from these heterocycles can be bonded via any suitable carbon atom.
  • Nitrogen heterocycles which carry a hydrogen atom (or a substituent) on a ring nitrogen atom, for [lacuna] pyrrole, imidazole, pyrrolidine, morpholine, piperazine etc. can also be bonded via a ring nitrogen atom, in particular if the nitrogen heterocycle concerned is bonded to a carbon atom.
  • a radical bonded via a carbon atom which is derived from 1,3-thiazole or from imidazole, can be bonded via the 2-position, the 4-position or the 5-position.
  • heterocyclic groups such as, for example, heteroaryl radicals
  • the substituents in heterocycles can be situated in any desired positions, for example in the 3-position and/or in the 4-position and/or in the 5-position in a 2-thienyl radical or 2-furyl radical, in the 2-position and/or in the 4-position and/or in the 5-position in a 3-thienyl radical or 3-furyl radical, in the 3-position and/or in the 4-position and/or in the 5-position and/or in the 6-position in a 2-pyridyl radical, in the 2-position and/or in the 4-position and/or in the 5-position and/or in the 6-position in a 3-pyridyl radical, in the 2-position and/or in the 3-position and/or in the 5-position and/or in the 6-position in a 4-pyridyl radical.
  • substituents which can occur are, for example, the substituents indicated in the definition of the group aryl, in the case of saturated or partially unsaturated heterocycles as further substituents also the oxo group and the thioxo group.
  • Substituents on a heterocycle and substituents on a carbocycle can also form a ring, thus further rings can be fused to a ring system so that, for example, cyclopenta-fused, cyclohexa-fused or benzo-fused rings can be present.
  • Suitable substituents on a substitutable nitrogen atom of a heterocycle are in particular, for example, unsubstituted (C 1 -C 5 )-alkyl radicals and aryl-substituted alkyl radicals, aryl radicals, acyl radicals such as CO—(C 1 -C 5 )-alkyl, or sulfonyl radicals such as SO 2 —(C 1 -C 5 )-alkyl.
  • Suitable nitrogen heterocycles can also be present as N-oxides or as quaternary salts having an anion derived from a physiologically tolerable acid as a counterion.
  • Pyridyl radicals can be present, for example, as pyridine N-oxides.
  • Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.
  • the present invention includes all stereoisomeric forms of the compounds of the formula I.
  • Asymmetric centers contained in the compounds of the formula I can all independently of one another have the S configuration or the R configuration.
  • the invention includes all possible enantiomers and diastereomers, as well as mixtures of two or more stereoisomeric forms, for example mixtures of enantiomers and/or diastereomers, in all ratios.
  • Enantiomers are thus included by the invention in enantiomerically pure form, both as dextrorotatory and as levorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in all ratios.
  • the invention In the presence of cisitrans isomerism the invention relates both to the cis form and the trans form and mixtures of these forms in all ratios.
  • Individual stereoisomers can be prepared, if desired, by resolution of a mixture according to customary methods, for example by chromatography or crystallization, by use of stereochemically homogeneous starting substances in the synthesis or by stereoselective synthesis. If appropriate, derivatization can be carried out before separation of stereoisomers. The separation of a stereoisomer mixture can be carried out at the stage of the compounds of the formula I or at the stage of an intermediate in the course of the synthesis. If mobile hydrogen atoms are present, the present invention also includes all tautomeric forms of the compounds of the formula I.
  • the invention also relates to the corresponding physiologically or toxicologically tolerable salts, in particular the pharmaceutically utilizable salts.
  • the compounds of the formula I which contain acidic groups can be present in these groups, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts and can be used according to the invention.
  • Examples of such salts are sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids.
  • protonatable, groups can be present and can be used according to the invention in the form of their acid addition salts with physiologically tolerable inorganic or organic acids, for example as salts with hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfamic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid etc.
  • physiologically tolerable inorganic or organic acids for example as salts with hydrogen chloride, hydrogen bro
  • the invention also includes internal salts or betaines (zwitterions). Salts can be obtained from the compounds of the formula I by customary processes known to the person skilled in the art, for example by combination with an organic or inorganic acid or base in a solvent or dispersant, or alternatively from other salts by anion exchange or cation exchange.
  • the present invention furthermore includes all solvates of compounds of the formula I, for example hydrates or adducts with alcohols, and also derivatives of the compounds of the formula I such as, for example, esters, and prodrugs and active metabolites.
  • a 1 is preferably phenyl, naphthyl or bicyclic heteroaryl, which can all be substituted by one or more identical or different radicals R 1 .
  • Bicydic heteroaryl representing A 1 is particularly preferably bicydic heteroaryl having 10 ring members, which preferably contains one or two nitrogen atoms, in particular one nitrogen atom, as ring heteroatoms.
  • bicyclic heteroaryl representing A 1 is a radical derived from quinoline.
  • a 2 together with the two atoms carrying the group R 2 —SO 2 —NH and the group CO—NH, preferably forms an aromatic ring, particularly preferably a benzene ring or a thiophene ring.
  • a 1 can be unsubstituted, that is only carry hydrogen atoms, or can be substituted as indicated by one or more, for example one, two, three or four, identical or different radicals R 1 .
  • a substituted radical A 1 is substituted by one, two or three, in particular one or two, radicals R 1 .
  • Radicals R 1 are preferably bonded to carbon atoms in A 1 which are not directly adjacent to the carbon atom which carries the group CO—NH. If A is phenyl, radicals R 1 are particularly preferably in the meta-position and/or in the para-position, relative to the carbon atom which carries the group CO—NH.
  • a phenyl radical representing A 1 carries a radical R 1 , this radical in many cases is particularly advantageously present in the para-position. If a phenyl radical representing A 1 carries a trifluoromethyl group as a radical R 1 , this is preferably in the meta-position. If a phenyl radical representing A 1 carries two radicals R 1 representing chlorine, the two chlorine atoms are preferably in positions 3 and 4.
  • Preferred radicals R 1 are halogen, in particular chlorine, trifluoromethyl, (C 3 -C 7 )-alkyl, carboxymethyl, CONR 6 R 5 , 5-membered to 7-membered heterocyclyl, —O-aryl, —CO—(C 1 -C 10 )-alkyl, —CO-aryl, —NH—CO—(C 1 -C 10 )-alkyl, —NH—CO-aryl, —N(CO—(C 1 -C 10 )-alkyl) 2 , —N(CO-aryl) 2 , —NH—SO 2 —(C 1 -C 10 )-alkyl, —NH—SO 2 —(C 1 -C 10 )-alkyl, —NH—SO 2 -aryl, —N(SO 2 -aryl) 2 and —N(SO 2 —(C 1 -C 10 )-alkyl) 2 , where all alky
  • R 5 R 6 representing R 1 , R 5 and R 6 , together with the nitrogen atom to which they are bonded, preferably form a 5-membered to 8-membered saturated or partially unsaturated ring, which in addition to the nitrogen atom carrying the groups R 5 and R 6 can also contain one or more further ring heteroatoms from the group consisting of N, O and S and which can be substituted as indicated above by one or more identical or different substituents.
  • a group of particularly preferred radicals R 1 is formed by the radicals halogen, in particular chlorine, trifluoromethyl, —O-aryl, —NH—CO—(C 1 -C 10 )-alkyl, —NH—CO-aryl, —NH—SO 2 —(C 1 -C 10 )-alkyl and —NH—SO 2 -aryl, where all alkyl radicals can be substituted by one or more identical or different radicals R 4 .
  • a further group of particularly preferred radicals R is formed by the radicals CONR 5 R 6 , —CO—(C 1 -C 10 )-alkyl, —CO-aryl, —NH—CO—(C 1 -C 10 )-alkyl, —NH—CO-aryl, —N(CO—(C 1 -C 10 )-alkyl) 2 , —N(CO-aryl) 2 , —NH—SO 2 —(C 1 -C 10 )-alkyl, —NH—SO 2 -aryl, —N(SO 2 -aryl) 2 and —N(SO 2 —(C 1 -C 10 )-alkyl) 2 , where all alkyl radicals can be substituted by one or more identical or different radicals R 4 .
  • R 2 is preferably aryl, particularly preferably phenyl or 5-membered or 6-membered heteroaryl, where the radicals can be unsubstituted or substituted as indicated above.
  • R 2 is phenyl, thienyl or pyrazolyl, which can all in each case be substituted by one or two identical or different radicals from the group consisting of halogen, CF 3 and (C 1 -C 3 )-alkyl.
  • the rings representing A 2 can be unsubstituted, that is only carry R 3 representing hydrogen, or be substituted as indicated, that is carry one or more radicals R 3 other than hydrogen.
  • the other substituent positions on the ring A 2 which do not carry any radical R 3 other than hydrogen, carry hydrogen atoms. If the ring A 2 carries one or more radicals R 3 which are other than hydrogen, it preferably carries one or two radicals R 3 of this type, in particular one radical R 3 of this type. Radicals R 3 of this type are preferably present in those positions of the ring A 2 which are not directly adjacent to the groups CO—NH and R 2 SO 2 —NH.
  • R 3 of this type is preferably (C 1 -C 4 )-alkyl, in particular methyl. If A 2 is an aromatic ring, in particular if A 2 is a benzene ring, R 3 of this type is preferably (C 1 -C 3 )-alkyl, methoxy, halogen or CF 3 , particularly preferably methyl or chlorine. If A 2 is an aromatic ring, in particular a benzene ring, it is very particularly preferred if this carries one chlorine atom as a substituent, that is if one radical R 3 representing chlorine is present and the other substituent positions on the benzene ring carry hydrogen atoms.
  • radicals R 3 other than hydrogen are preferably in positions 4 and/or 5. If only one radical R 3 of this type is present on a benzene ring representing A 2 , this radical is preferably present in position 5 (relative to the group CO—NH in the 1-position).
  • R 4 is preferably substituted by one, two or three, in particular one or two, identical or different radicals R 4 .
  • R 4 is preferably hydroxyl, (C 1 -C 4 )-alkyloxy, di-((C 1 -C 4 )-alkyl)amino or heteroaryl.
  • R 5 and R 6 are preferably independently of one another hydrogen, (C 1 -C 9 )-alkyl, —(C 1 -C 3 )-alkyl-O—(C 1 -C 4 )-alkyl or 5-membered or 6-membered aryl or, together with the nitrogen atom carrying R 5 and R 6 , form a 5-membered to 7-membered heteroc cle which additionally to the nitrogen atom carrying the groups R 5 and R 6 can also contain a further ring heteroatom from the group consisting of N, O and S and which can be substituted by one or more, for example one, two, three or four, identical or different radicals as indicated above, in particular by radicals from the group consisting of (C 1 -C 3 )-alkyl, 5-membered aryl and 6-membered aryl.
  • R 5 and R 6 together with the nitrogen atom carrying them, form a 5-membered to 7-membered heterocycle which in addition to the nitrogen atom carrying the groups R 5 and R 6 can also contain a further ring heteroatom from the group consisting of N, O and S and which can be substituted by one or more, for example one, two, three or four, identical or different radicals as indicated above, in particular by radicals from the group consisting of (C 1 -C 3 )-alkyl, 5-membered aryl and 6-membered aryl.
  • such a ring which is formed from R 5 and R 6 together with the nitrogen atom carrying them, is derived from morpholine, thiomorpholine, 1,1-dioxo-thiomorpholine, 1-oxothiomorpholine, 3,5-dimethylmorpholine, cis-3,5-dimethylmorpholine, 1-(pyrimidin-2-yl)piperazine, piperidin-4-carboxamide, 1-(2-hydroxyethyl)piperazine, 1-methylpiperazine, 1-ethylpiperazine, from 1-arylpiperazines, from ethyl piperazine-1-carboxylate, piperidine, 2-methylpiperidine, 4-hydroxypiperidine, from 4-oxopiperidine or a ketal thereof such as 1,4-dioxa-8-azaspiro[4.5]decane, from tetrahydropyridine, tetrahydropyrimidine, 1-methylhomopiperazine, thiazolidine,
  • such a ring which is formed from R 5 and R 6 together with the nitrogen atom carrying them is derived from morpholine, thiomorpholine, 1,1-dioxothiomorpholine, 1-oxothiomorpholine, 3,5-dimethylmorpholline, cis-3,5-dimethylmorpholine, 1-(pyrimidin-2-yl)-piperazine, piperidine-4-carboxamide, 1,2,3,4-tetrahydroisoquinoline or 2,3-dihydro-1H-isoindole.
  • R 8 is preferably hydrogen, (C 1 -C 3 )-alkyl, di-((C 1 -C 4 )-alkyl)amino or —(C 1 -C 3 )-alkyl-O—(C 1 -C 4 )-alkyl.
  • R 9 is preferably hydrogen, (C 1 -C 3 )-alkyl or acetyl.
  • Aryl is preferably phenyl or heteroaryl, in particular phenyl or 5-membered or 6-membered heteroaryl.
  • Preferred substituents in aryl radicals are halogen, CF 3 , (C 1 -C 3 )-alkyl, cyano, nitro and (C 1 -C 3 )-alkyloxy, particularly preferred substituents are CF 3 , chlorine, methyl and methoxy.
  • Heteroaryl preferably represents radicals which are derived from the heteroaromatics thiophene, pyrazole, thiazole, oxazole, pyridine, pyrimidine, pyridazine and tetrazole.
  • Heterocyclyl preferably represents radicals which are derived from saturated heterocycles, in particular radicals which are derived from pyrrolidine, piperidine, from N-alkylpiperazines, from morpholine, from dialkylmorpholines, from thiomorpholine or tetrahydrofuran.
  • n therein is preferably 1 or 2, particularly preferably 2.
  • Preferred compounds according to the present invention are compounds of the formula I in which one or more of the radicals contained therein have preferred meanings, where all combinations of preferred substituent definitions are the subject of the present invention. Also, of all preferred compounds of the formula I, the present invention relates to all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts.
  • a group of preferred compounds according to the present invention is formed, for example, from those compounds of the formula I in which A 1 is phenyl which carries a radical R 1 in the 4-position; the ring A 2 which includes the carbon atoms which carry the groups CO—NH— and NH—SO 2 R 2 is a benzene ring or a thiophene ring; and R 1 is a substituent from the group consisting of CO—(C 1 -C 10 )-alkyl, CO-aryl, CO—NR 5 R 6 , —NH—CO—(C 1 -C 10 )-alkyl, —NH—CO-aryl, —N(CO—(C 1 -C 10 )-alkyl) 2 , —N(CO-aryl) 2 , —NH—SO 2 —(C 1 -C 10 )-alkyl, —NH—SO 2 -aryl, —N(SO 2 —(C 1 -C 10 )-alkyl
  • an aminocarboxylic acid of the formula II can first be reacted with a sulfonyl chloride of the formula R 2 —SO 2 —Cl or a sulfonic anhydride in the presence of a base in a solvent such as water, pyridine or an ether.
  • Suitable bases are inorganic bases such as, for example, sodium carbonate or organic bases such as, for example, pyridine or triethylamine.
  • the sulfonylaminocarboxylic acid of the formula III obtained can then be activated, for example, by reaction with a chlorinating agent such as, for example, phosphorus pentachloride, phosphorus oxychloride or thionyl chloride in an inert solvent to give an acid chloride of the formula IV and then reacted with an arylamine.
  • a chlorinating agent such as, for example, phosphorus pentachloride, phosphorus oxychloride or thionyl chloride in an inert solvent to give an acid chloride of the formula IV and then reacted with an arylamine.
  • the activation of the carboxylic acid group in the compound of the formula III can also be carried out in another way, for example by one of the numerous methods familiar to the person skilled in the art, which are used in peptide chemistry for the linkage of amide bonds, for example by conversion into a mixed anhydride or an activated ester or using a carbodiimide such as dicyclohexylcarbodiimide.
  • the reaction of the activated sulfonylaminocarboxylic acid with an arylamine is advantageously carried out in an inert solvent such as, for example, pyridine, tetrahydrofuran or toluene with without without addition of an inert auxiliary base, for example of a tertiary amine or of pyridine.
  • an inert solvent such as, for example, pyridine, tetrahydrofuran or toluene
  • an inert auxiliary base for example of a tertiary amine or of pyridine.
  • the activated carboxylic acids can also first be reacted with an arylamine of the formula R 1a —A 1 —NH 2 , in which R 1a is hydrogen or one or more of the groups R 1 which can be contained as substituents in A 1 , or R 1a is one or more groups which can be converted into groups R 1 according to the above definition.
  • R 1a can be a hydrogen atom which is replaced in an electrophilic reaction by another radical such as, for example, a halogen atom or an aldehyde group, or an ester group which is converted into an amide group.
  • the conversion of the reaction product of the formula V first obtained into a compound of the formula I can be carried out by standard processes.
  • the activating action of the nitro group on the ring A 2 can be utilized and a suitable radical R 3 , for example a halogen atom, can be replaced by another radical R 3 by reaction with a nucleophile, for example an amine.
  • a suitable radical R 3 for example a halogen atom
  • R 3 can be replaced by another radical R 3 by reaction with a nucleophile, for example an amine.
  • the reduction of the nitro group to the amino group can be carried out, for example, by catalytic hydrogenation in the presence of a noble metal catalyst or preferably in the presence of Raney nickel in a solvent such as ethanol, glacial acetic acid or ethanolic hydrochloric acid, or by reduction with a base metal such as tin, zinc or iron in the presence of acid.
  • the reduction can also be carried out, for example, with tin(II) chloride or by reaction with sodium dithionite, advantageously, for example, in a mixture of methanol, tetrahydrofuran and water as the solvent.
  • an arylamine of the formula A 1 —NH 2 an arylamine of the formula R 1a —A 1 —NH 2 can also in turn be employed, in which R 1a has the meaning indicated above, and the group or the groups R 1a are then converted into the group or the groups R 1 .
  • the compounds of the formula I obtained can optionally be purified by customary purification methods, for example by recrystallization or chromatography.
  • Starting compounds for the preparation of the compounds of the formula I are commercially obtainable or can be prepared according to or analogously to literature procedures.
  • the compounds of the formula I bring about an increase in the cGMP concentration by means of the activation of soluble guanylate cyclase (sGC) and are therefore valuable agents for the therapy and prophylaxis of diseases which are associated with a low or reduced cGMP level or are caused by such a level or for whose therapy or prophylaxis an increase or normalization in the cGMP level present is desired.
  • sGC soluble guanylate cyclase
  • the activation of sGC by the compounds of the formula I can be investigated, for example, in the activity assay described below.
  • Diseases and pathological conditions which are associated with a low cGMP level or in which an increase or normalization in the cGMP level is desired and for whose therapy and prophylaxis compounds of the formula I can be employed are, for example, cardiovascular disorders such as endothelial dysfunction, diastolic dysfunction, atherosclerosis, high blood pressure, stable and unstable angina pectoris, thromboses, restenoses, myocardial infarct, strokes, cardiac insufficiency or pulmonary hypertension, or, for example, erectile dysfunction, bronchial asthma, chronic renal insufficiency and diabetes.
  • Compounds of the formula I can moreover be employed in the therapy of liver cirrhosis and for improving restricted learning capacity or memory power.
  • the compounds of the formula I are employed in cardiovascular disorders such as goendothelial dysfunction, diastolic dysfunction, atherosclerosis, high blood pressure, stable and unstable angina pectoris, thromboses, restenoses, myocardial infarct, strokes, cardiac insufficiency or pulmonary hypertension, in erectile dysfunction or for improving restricted learning capacity or memory power.
  • cardiovascular disorders such as goendothelial dysfunction, diastolic dysfunction, atherosclerosis, high blood pressure, stable and unstable angina pectoris, thromboses, restenoses, myocardial infarct, strokes, cardiac insufficiency or pulmonary hypertension, in erectile dysfunction or for improving restricted learning capacity or memory power.
  • the compounds of the formula I and their physiologically tolerable salts can thus be used in animals, preferably in mammals, and in particular in man, as pharmaceuticals on their own, in mixtures with one another or together with other active compounds.
  • the present invention therefore in particular also relates to the use of compounds of the formula I and their physiologically tolerable salts for the production of a medicament for the therapy or prophylaxis of the abovementioned syndromes, and the use for the production of a medicament for increasing or normalizing a disturbed cGMP balance.
  • the invention likewise relates to the use of the compounds of the formula I and their physiologically tolerable salts for the activation of soluble guanylate cyclase, their use for the therapy or prophylaxis of the abovementioned syndromes and their use for increasing or normalizing a disturbed cGMP balance.
  • compositions according to the present invention can be administered orally, for example in the form of pills, tablets, film-coated tablets, coated tablets, granules, hard and soft gelatin capsules, aqueous, alcoholic or oily solutions, syrups, emulsions or suspensions, or rectally, for example in the form of suppositories.
  • Administration can also be carried out parenterally, for example subcutaneously, intramuscularly or intravenously in the form of injection solutions or infusion solutions.
  • administration forms are, for example, percutaneous or topical application, for example in the form of ointments, tinctures, sprays or transdermal therapeutic systems, or administration by inhalation in the form of nasal sprays or aerosol mixtures, or, for example, microcapsules, implants or rods.
  • the preferred administration form depends, for example, on the disease to be treated and its severity.
  • the medicaments according to the invention can be produced according to known standard processes for the production of pharmaceutical preparations.
  • one or more compounds of the formula I and/or their physiologically tolerable salts are brought, together with one or more solid or liquid pharmaceutical vehicles and/or additives or auxiliaries and, if desired, in combination with other pharmaceutical active compounds having therapeutic or prophylactic action, into a suitable administration form or dose form, which can then be used as a pharmaceutical in human or veterinary medicine.
  • the pharmaceutical preparations contain a therapeutically or prophylactically active dose of the compounds of the formula I and/or their physiologically tolerable salts, which normally makes up 0.5 to 90% by weight of the pharmaceutical preparation.
  • Suitable vehicles for the preparation of solutions for example injection solutions, or of emulsions or syrups are, for example, water, physiological saline solution, alcohols such as ethanol, glycerol, polyols, sucrose, invert sugar, glucose, mannitol, vegetable oils etc.
  • the compounds of the formula I and their physiologically tolerable salts can also be lyophilized and the lyophilizates obtained used, for example, for the production of injection preparations or infusion preparations.
  • Suitable vehicles for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid.
  • the pharmaceutical preparations can additionally contain customary additives, for example fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweetening agents, colorants, flavorings or aromatizers, thickening agents, diluents, buffer substances, furthermore solvents or solubilizers or agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants.
  • customary additives for example fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweetening agents, colorants, flavorings or aromatizers, thickening agents, diluents, buffer substances, furthermore solvents or solubilizers or agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants.
  • the dose of the active compound of the formula I to be administered and/or of one of [lacuna] physiologically tolerable salts depends on the individual case and is to be suited to the individual conditions as customary for an optimal action. Thus it depends on the nature and severity of the disease to be treated, on the sex, age, weight and individual responsiveness of the human or animal to be treated, on the potency and duration of action of the compounds employed, on whether the therapy is acute or chronic or prophylaxis is carried out, or on whether further active compounds are administered in addition to compounds of the formula I.
  • a daily dose of approximately 0.01 to 100 mg/kg, preferably 0.1 to 10 mg/kg, in particular 0.3 to 5 mg/kg (in each case mg/kg of body weight) is appropriate in the case of administration to an adult of about 75 kg in weight to achieve the desired action.
  • the daily dose can be administered in a single dose or, in particular in the case of administration of relatively large amounts, divided into a number of, for example two, three or four, individual doses. If appropriate, depending on individual behavior, it may be necessary to deviate upward or downward from the daily dose indicated.
  • Pharmaceutical preparations normally contain 0.2 to 500 mg, preferably 1 to 200 mg, of active compound of the formula I and/or its physiologically tolerable salts.
  • the compounds of the formula I activate soluble guanylate cyclase, especially by binding in the heme binding pocket of the enzyme.
  • pharmaceutical active compounds in human medicine and veterinary medicine, they can also be employed as a scientific tool or as an aid for biochemical investigations in which an effect on guanylate cyclase of this type is intended, and also for diagnostic purposes, for example in the in vitro diagnosis of cell or tissue samples.
  • the compounds of the formula I and their salts as already mentioned above, can serve as intermediates for the preparation of further pharmaceutical active compounds.
  • the formula I with the above general definition of the radicals also includes compounds which have not yet been described.
  • the present invention also relates to the not yet known compounds of the formula I as such.
  • the present invention thus also relates to compounds of the formula Ii
  • a 1 is a radical from the group consisting of phenyl, naphthyl and heteroaryl, which can all be substituted by one or more identical or different radicals R 1 ;
  • the ring A 2 which includes the carbon atoms which carry the groups CO—NH— and NH—SO 2 R 2 , is a benzene ring, a naphthalene ring, a saturated or partially unsaturated 3-membered to 7-membered carbocycle, a saturated, partially unsaturated or aromatic monocyclic 5-membered to 7-membered heterocycle which contains one or more ring heteroatoms from the group consisting of N, O and S, or a saturated, partially unsaturated or aromatic bicyclic 8-membered to 10-membered heterocycle which contains one or more ring heteroatoms from the group consisting of N, O and S;
  • R 1 is halogen, aryl, CF 3 , NO 2 , OH, —O—(C 1 -C 7 )-alkyl, —O—(C 2 -C 4 )-alkyl-—(C 1 -C 7 )-alkyl, —O-aryl, (C 1 -C 2 )-alkylenedioxy, NR 5 R 6 , CN, CO—NR 5 R 6 COOH, CO—O—(C 1 -C 5 )-alkyl, heterocyclyl, CHO, CO—(C 1 -C 10 )-alkyl, CO-aryl or (C 1 -C 10 )-alkyl which can be substituted by one or more identical or different radicals R 4 ;
  • R 2 is aryl, heterocyclyl, NR 5 R 6 ;
  • R 3 is one or more identical or different substituents from the group consisting of halogen, CF 3 , OH, —O—(C 1 -C 10 )-alkyl, —O—(C 1 -C 7 )-alkyl-R 7 , —O-aryl, SH, —S—(C 1 -C 10 )-alkyl, —S—(C 1 -C 7 )-alkyl-R 7 , —S—aryl, (C 1 -C 3 )-alkylenedioxy, CN, NO 2 , NR 8 R 9 , CO—NR 5 R 6 , COOH, CO—O—(C 1 -C 5 )-alkyl, heterocyclyl, S(O) n —(C 1 -C 7 )-alkyl, S(O) n -aryl, S(O) n —NR 5 R 6 and (C 1 -C 7 )-alkyl which can be substitute
  • R 4 is fluorine, OH, —O—(C 1 -C 10 )-alkyl, —O—(C 1 -C 7 )-alkyl-R 7 , —O-aryl, SH, —S—(C 1 -C 10 )-alkyl, —S—(C 1 -C 7 )-alkyl-R 7 , —S-aryl, —P(O)(O—(C 1 -C 5 )-alkyl) 2 , —P(O)(OH) 2 , CN, NR 8 R 9 , CO—NH 2 , CO—NH—(C 1 -C 3 )-alkyl, CO—N((C 1 -C 3 )-alkyl) 2 , COOH, CO—O—(C 1 -C 5 )-alkyl, heterocyclyl or oxo;
  • R 5 is hydrogen, (C 1 -C 10 )-alkyl which can be substituted by one or more identical or different substituents R 4 and/or by aryl, or is aryl, heterocyclyl, CO—(C 1 -C 10 )-alkyl, CO-aryl, CO-heterocyclyl, SO 2 —(C 1 -C 10 )-alkyl, SO 2 -aryl or SO 2 -heterocyclyl;
  • R 6 independently of R 5 , has one of the meanings indicated for R 5 , or R 5 and R 6 , together with the nitrogen atom to which they are bonded, form a 5-membered to 8-membered saturated or partially unsaturated ring which, in addition to the nitrogen atom carrying the groups R 5 and R 6 , can also contain one or more further ring heteroatoms from the group consisting of N, O and S and which can be substituted by one or more identical or different substituents from the group consisting of fluorine, (C 1 -C 5 )-alkyl, (C 1 -C 3 )-hydroxyalkyl, —(C 1 -C 3 )-alkyl-O—(C 1 -C 4 )-alkyl, aryl, CF 3 , OH, —O—(C 1 -C 7 )-alkyl, —O-aryl, —O—(C 2 -C 4 )-alkyl-O—(C 1 -
  • R 7 is OH, —O—(C 1 -C 7 )-alkyl, NH 2 , —NH—(C 1 -C 4 )-alkyl or —N((C 1 -C 4 )-alkyl) 2 , where in the substituent N((C 1 -C 4 )-alkyl) 2 the two alkyl groups can be linked by a single bond and then together with the nitrogen atom carrying hem form a 5-membered to 7-membered ring which, in addition to the nitrogen atom and the carbon atoms, can additionally also contain an oxygen atom, a sulfur atom or a group NR 5 as a ring member;
  • R 8 is hydrogen or (C 1 -C 7 )-alkyl which can be substituted by one or more identical or different substituents from the group consisting of OH, —O—(C 1 -C 5 )-alkyl, NH 2 , —NH—(C 1 -C 4 )-alkyl and —N((C 1 -C 4 )-alkyl) 2 , where in the substituent N((C 1 -C 4 )-alkyl) 2 the two alkyl groups can be linked by a single bond and then, together with the nitrogen atom carrying them, form a 5-membered to 7-membered ring which, in addition to the nitrogen atom and the carbon atoms, can additionally also contain an oxygen atom, a sulfur atom or a group NR 5 as a ring member;
  • R 9 independently of R has one of the meanings of R 8 or is CO—(C 1 -C 4 )-alkyl;
  • aryl is phenyl, naphthyl or heteroaryl, which can all be substituted by one or more identical or different substituents from the group consisting of halogen, (C 1 -C 5 )-alkyl, phenyl, tolyl, CF 3 , NO 2 , OH, —O—(C 1 -C 5 )-alkyl, —O—(C 2 -C 4 )-alkyl-O—(C 1 -C 3 )-alkyl, (C 1 -C 2 )-alkylenedioxy, NH 2 , —NH—(C 1 -C 3 )-alkyl, —N((C 1 -C 3 )-alkyl) 2 , NH—CHO, —NH—CO—(C 1 -C 5 )-alkyl, CN, CO—NH 2 , CO—NH—(C 1 -C 3 )-alkyl, CO—N((C 1 -
  • heteroaryl is the radical of a monocyclic 5-membered or 6-membered aromatic heterocycle or a bicyclic 8-membered to 10-membered aromatic heterocycle, which in each case contain one or more ring heteroatoms from the group consisting of N, O and S;
  • heterocyclyl is the radical of a monocyclic or polycyclic, 5-membered to 11-membered saturated or partially unsaturated heterocycle, which contains one or more ring heteroatoms from the group consisting of N, O and S and which can be substituted by one or more identical or different substituents from the group consisting of fluorine, (C 1 -C 5 )-alkyl, OH, —O—(C 1 -C 5 )-alkyl, —O—(C 2 -C 4 )-alkyl-O—(C 1 -C 3 )-alkyl, NH 2 , —NH—(C 1 -C 3 )-alkyl, —N((C 1 -C 3 )-alkyl) 2 , CN, CO—NH 2 , CO—NH—(C 1 -C 3 )-alkyl, CO—N((C 1 -C 3 )-alkyl) 2 , COOH and CO—O—(C
  • n 0, 1 or 2;
  • n 2, 3 or 4;
  • a 1 is phenyl
  • a 2 together with the carbon atoms carrying the groups CO—NH and R 2 SO 2 —NH forms a benzene ring
  • R 1 is radicals from the group consisting of halogen, phenyloxy, naphthyloxy, 1,3-benzothiazol-2-yloxy, pyrimidin4-yloxy and pyrimidin6-yloxy, which can all be unsubstituted or substituted;
  • a 1 or R 2 is 2,1,3-benzothiadiazol-4-yl
  • a 1 is 2-hydroxyphenyl, 2-ethoxycarbonylmethoxyphenyl, 2-carboxyphenyl, 2-carboxyalkylphenyl or 2arbamoylphenyl;
  • the ring A 2 in the compounds of the formula ii can also have, for example, the meanings shown in the formulae Ia, Ib, Ic, Id, Ie, If, Ig and Ih, if these are not excluded in the definition of the substituents in the formula ii.
  • radicals in the formula I also apply correspondingly to the radicals in the formula Ii.
  • preferred compounds of the formula Ii are those compounds in which one or more of the radicals have preferred meanings, where all combinations of preferred substituent definitions are a subject of the present invention.
  • a group of preferred compounds of the formula Ii is formed, for example, of those compounds in which A 1 is phenyl which carries a radical R 1 in the 4-position; the ring A 2 , which includes the carbon atoms which carry the groups CO—NH—and NH—SO 2 R 2 , is a benzene ring or a thiophene ring; and R 1 is a substituent from the group consisting of CO—(C 1 -C 10 )-alkyl, CO-aryl, CO—NR 5 R 6 , —NH—CO—(C 1 -C 10 )-alkyl, —NH—CO-aryl, —N(CO—(C 1 -C 10 )-alkyl) 2 , —N(CO-aryl) 2 , —NH—SO 2 —(C 1 -C 10 )-alkyl, —NH—SO 2 -aryl, —N(SO 2 —(C 1 -C 10 )-alkyl
  • the present invention also relates to specific compounds of the formula I as such, in which the ring A 2 , which includes the carbon atoms which carry the groups CO—NH— and NH—SO 2 R, carries no further substituents, that is compounds of the formula I in which R 3 is hydrogen.
  • a 1 , A 2 and R 1 preferably have the meanings which are indicated above for the preferred compounds of the formula Ii.
  • the present invention thus also relates to the compounds of the formula Ik,
  • the ring A 2 which includes the carbon atoms which carry the groups CO—NH— and NH—SO 2 R 2 , is a benzene ring or a thiophene ring;
  • R 1 is a substituent from the group consisting of CO—(C 1 -C 10 )-alkyl, CO-aryl, CO—NR 5 R 6 , —NH—CO—(C 1 -C 10 )-alkyl, —NH—CO-aryl, —N(CO—(C 1 -C 10 )-alkyl) 2 , —N(CO-aryl) 2 , —NH—SO 2 —(C 1 -C 10 )-alkyl, —NH—SO 2 -aryl, —N(SO 2 —(C 1 -C 10 )-alkyl) 2 and —N(SO 2 -aryl) 2 , in which all alkyl radicals can be substituted by one or more identical or different radicals R 4 ;
  • R 2 is aryl, heterocyclyl or NR 5 R 6 ;
  • R 3 is one or more identical or different substituents from the group consisting of hydrogen, halogen, CF 3 , OH, —O—(C 1 -C 10 )-alkyl, —O—(C 1 -C 7 )-alkyl-R 7 , —O-aryl, SH, —S—(C 1 -C 10 )-alkyl, —S—(C 1 -C 7 )-alkyl-R 7 , —S-aryl, (C 1 -C 2 )-alkylenedioxy, CN, NO 2 , NR 8 R 9 , CO—NR 5 R 6 , COOH, CO—O—(C 1 -C 5 )-alkyl, heterocyclyl, S(O) n —(C 1 -C 7 )-alkyl, S(O) n -aryl, S(O) n —NR 5 R 6 and (C 1 -C 7 )-alkyl which can
  • R 4 is fluorine, OH, —O—(C 1 -C 10 )-alkyl, —O—(C 1 -C 7 )-alkyl-R 7 , —O-aryl, SH, —S—(C 1 -C 10 )-alkyl, —S—(C 1 -C 7 )-alkyl-R 7 , —S-aryl, —P(O)(O—(C 1 -C 5 )-alkyl) 2 , —P(O)(OH) 2 , CN, NR 8 R 9 , CO—NH 2 , CO—NH—(C 1 -C 3 )-alkyl, CO—N((C 1 -C 3 )-alkyl) 2 , COOH, CO—O—(C 1 -C 5 )-alkyl, heterocyclyl or oxo;
  • R 5 is hydrogen, (C 1 -C 10 )-alkyl which can be substituted by one or more identical or different substituents R 4 and/or by aryl, or is aryl, heterocyclyl, CO—(C 1 -C 10 )-alkyl, CO-aryl, CO-heterocyclyl, SO 2 —(C 1 -C 10 )-alkyl, SO 2 -aryl or SO 2 -heterocyclyl;
  • R 6 independently of R 6 , has one of the meanings indicated for R 5 , or R 5 and R 6 , together with the nitrogen atom to which they are bonded, form a 5-membered to 8-membered saturated or partially unsaturated ring, which in addition to the nitrogen atom carrying the groups R 5 and R 6 can also contain one or more further ring heteroatoms from the group consisting of N, O and S and which can be substituted by one or more identical or different substituents from the group consisting of fluorine, (C 1 -C 5 )-alkyl, (C 1 -C 3 )-hydroxyalkyl, —(C 1 -C 3 )-alkyl-O—(C 1 -C 4 )-alkyl, aryl, CF 3 , OH, —O—(C 1 -C 7 )-alkyl, —O-aryl, —O—(C 2 -C 4 )-alkyl-O—(C 1 -C 7
  • R 7 is OH, —O—(C 1 -C 7 )-alkyl, NH 2 , —NH—(C 1 -C 4 )-alkyl or —N((C 1 -C 4 )-alkyl) 2 , where in the substituent N((C 1 -C 4 )-alkyl) 2 the two alkyl groups can be linked by a single bond and then together with the nitrogen atom carrying them form a 5-membered to 7-membered ring which in addition to the nitrogen atom and the carbon atoms can additionally also contain an oxygen atom, a sulfur atom or a group NR 5 as a ring member;
  • R 8 is hydrogen or (C 1 -C 7 )-alkyl which can be substituted by one or more identical or different substituents from the group consisting of OH, —O—(C 1 -C 5 )-alkyl, NH 2 , —NH—(C 1 -C 4 )-alkyl and —N((C 1 -C 4 )-alkyl) 2 , where in the substituent N((C 1 -C 4 )-alkyl) 2 the two alkyl groups can be linked by a single bond and then together with the nitrogen atom carrying them form a 5-membered to 7-membered ring which in addition to the nitrogen atom and the carbon atoms can additionally also contain an oxygen atom, a sulfur atom or a group NR 5 as a ring member;
  • R 9 independently of R 8 , has one of the meanings of R 8 or is CO—(C 1 -C 4 )-alkyl;
  • aryl is phenyl, naphthyl or heteroaryl, which can all be substituted by one or more identical or different substituents from the group consisting of halogen, (C 1 -C 5 )-alkyl, phenyl, tolyl, CF 3 , NO 2 , OH, —O—(C 1 -C 5 )-alkyl, —O—(C 2 -C 4 )-alkyl-O—(C 1 -C 3 )-alkyl, (C 1 -C 2 )-alkylenedioxy, NH 2 , —NH—(C 1 -C 3 )-alkyl, —N((C 1 -C 3 )-alkyl) 2 , NH—CHO, —NH—CO—(C 1 -C 5 )-alkyl, CN, CO—NH 2 , CO—NH—(C 1 -C 3 )-alkyl, CO—N((C 1 -
  • heteroaryl is the radical of a monocyclic 5-membered or 6-membered aromatic heterocycle or of a bicyclic 8-membered to 10-membered aromatic heterocycle which in each case contain one or more ring heteroatoms from the group consisting of N, O and S;
  • heterocyclyl is the radical of a monocyclic or polycyclic, 5-membered to 11-membered saturated or partially unsaturated heterocycle which contains one or more ring heteroatoms from the group consisting of N, O and S and which can be substituted by one or more identical or different substituents from the group consisting of fluorine, (C 1 -C 5 )-alkyl, OH, —O—(C 1 -C 5 )-alkyl, —O—(C 2 -C 4 )-alkyl-O—(C 1 -C 3 )-alkyl, NH 2 , —NH—(C 1 -C 3 )-alkyl, —N((C 1 -C 3 )-alkyl) 2 , CN, CO—NH 2 , CO—NH—(C 1 -C 3 )-alkyl, CO—N((C 1 -C 3 )-alkyl) 2 , COOH and CO—O—(C 1
  • n 0, 1 or 2;
  • n 2, 3 or 4;
  • the ring A 2 in the compounds of the formula Ik can also, for example, have the meanings shown in the formulae Ia, If, Ig and Ih. All preferred meanings of the radicals in the formula I also apply correspondingly to the radicals in the formula Ik. Likewise, preferred compounds of the formula Ik are those compounds in which one or more of the radicals have preferred meanings, where all combinations of preferred substituent definitions are a subject of the present invention.
  • the present invention also relates to processes for the preparation of the compounds of the formulae Ii and Ik defined above by the synthesis process described above, the compounds of the formulae Ii and Ik and their physiologically tolerable salts for use as pharmaceuticals and pharmaceutical preparations which contain an efficacious dose of at least one compound of the formulae Ii or Ik or of a physiologically tolerable salt thereof as active constituent in addition to customary pharmaceutically acceptable vehicles and/or additives.
  • sGC soluble guanylate cyclase
  • GTP guanosine triphosphate
  • cGMP cyclic guanosine monophosphate
  • EIA enzyme immunoassay
  • the sGC employed had been isolated from bovine lung (see Methods in Enzymology, Volume 195, p. 377).
  • the test solutions (100 ⁇ l per well) contained 50 mM triethanolamine (TEA) buffer (pH 7.5), 3 mM MgCl 2 , 3 mM reduced glutathione (GSH), 0.1 mM GTP, 1 mM 3-isobutyl-1-methylxanthine (IBMX), suitably diluted enzyme solution and the test substance or, in the control experiments, solvent.
  • the test substances were dissolved in dimethyl sulfoxide (DMSO) and the solution was diluted with DMSO/water such that the final concentration c of test substance in the test batch had the value indicated below.
  • DMSO dimethyl sulfoxide
  • the DMSO concentration in the test batch was 5% (v/v).
  • the reaction was started by addition of the sGC.
  • the reaction mix was incubated at 37° C. for 15 to 20 minutes and then stopped by ice-cooling and addition of the stop reagent (50 mM EDTA, pH 8.0).
  • An aliquot of 50 ⁇ l was taken and employed for the determination of the cGMP content using the acetylation protocol of the Amersham cGMP EIA kit.
  • the absorption of the samples was measured at 450 nm (reference wavelength 620 nm) in a microtiter plate reading apparatus.
  • the cGMP concentration was determined by means of a calibration curve, which was obtained under the same experimental conditions.
  • the activation of the sGC by a test substance is indicated as n-fold stimulation of the basal enzyme activity which was found in the control experiments (with solvent instead of test substance) (calculated according to the formula
  • n-fold stimulation [cGMP] test substance /[cGMP] control ).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
US09/743,199 1998-07-08 1999-06-25 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators Expired - Lifetime US6548547B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/349,907 US6809089B2 (en) 1998-07-08 2003-01-24 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators
US10/957,980 US7351703B2 (en) 1998-07-08 2004-10-05 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19830431A DE19830431A1 (de) 1998-07-08 1998-07-08 Sulfonylamino-carbonsäure-N-arylamide als Guanylatcyclase-Aktivatoren
DE19830431 1998-07-08
PCT/EP1999/004427 WO2000002850A2 (fr) 1998-07-08 1999-06-25 N-arylamides d'acide sulfonylaminocarboxylique utilises comme activateurs de la guanylate cyclase

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/004427 A-371-Of-International WO2000002850A2 (fr) 1998-07-08 1999-06-25 N-arylamides d'acide sulfonylaminocarboxylique utilises comme activateurs de la guanylate cyclase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/349,907 Continuation US6809089B2 (en) 1998-07-08 2003-01-24 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators

Publications (1)

Publication Number Publication Date
US6548547B1 true US6548547B1 (en) 2003-04-15

Family

ID=7873292

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/743,199 Expired - Lifetime US6548547B1 (en) 1998-07-08 1999-06-25 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators
US10/349,907 Expired - Lifetime US6809089B2 (en) 1998-07-08 2003-01-24 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators
US10/957,980 Expired - Lifetime US7351703B2 (en) 1998-07-08 2004-10-05 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/349,907 Expired - Lifetime US6809089B2 (en) 1998-07-08 2003-01-24 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators
US10/957,980 Expired - Lifetime US7351703B2 (en) 1998-07-08 2004-10-05 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators

Country Status (14)

Country Link
US (3) US6548547B1 (fr)
EP (1) EP1095015B1 (fr)
JP (1) JP4422335B2 (fr)
KR (1) KR101021042B1 (fr)
AR (1) AR019231A1 (fr)
AT (1) ATE296800T1 (fr)
AU (1) AU5155399A (fr)
BR (1) BR9911942B1 (fr)
CA (1) CA2336702C (fr)
DE (2) DE19830431A1 (fr)
DK (1) DK1095015T3 (fr)
ES (1) ES2242407T3 (fr)
PT (1) PT1095015E (fr)
WO (1) WO2000002850A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186145A1 (en) * 1998-07-08 2004-09-23 Aventis Pharma Deutschland Gmbh. Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them
US6809089B2 (en) * 1998-07-08 2004-10-26 Aventis Pharma Deutschland Gmbh Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators
US20070015762A1 (en) * 1999-11-26 2007-01-18 Yasuyuki Kawanishi NPY Y5 antagonist
US20080045540A1 (en) * 2005-01-04 2008-02-21 Sanofi-Aventis Deutschland Gmbh Sulfonyl pyrrolidines, method for producing the same and their use as drugs
US20090021075A1 (en) * 2007-07-20 2009-01-22 Nec Electronics Corporation Semiconductor device

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5881000A (en) * 1999-06-24 2001-01-09 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
AU2001270029A1 (en) * 2000-06-21 2002-01-02 Smith Kline Beecham Corporation Macrophage scavenger receptor antagonists
US6716879B2 (en) 2000-08-30 2004-04-06 Compass Pharmaceuticals, Llc Methods for anti-tumor therapy
DE10046029A1 (de) * 2000-09-18 2002-03-28 Bayer Ag Indazole
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
WO2005085188A2 (fr) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Composes et procedes pour la therapie antitumorale
JPWO2006077901A1 (ja) * 2005-01-20 2008-06-19 塩野義製薬株式会社 Ｃｔｇｆ発現阻害剤
JP7357009B2 (ja) 2018-06-01 2023-10-05 プロメガ コーポレイション Ｏｐｌｏｐｈｏｒｕｓルシフェラーゼ由来生物発光性複合体の阻害剤

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US994730A (en) * 1910-10-06 1911-06-13 Jesse M Evans Automatic funnel.
GB865735A (en) * 1957-12-24 1961-04-19 Geigy Ag J R Process for the production of new aminobenzoic acid derivatives and their use in pest control
FR1579473A (fr) 1966-10-21 1969-08-29
JPS5916871A (ja) * 1982-07-20 1984-01-28 Shionogi & Co Ltd スルホンアミド系ベンズアミド類
JPS59162547A (ja) * 1983-03-07 1984-09-13 Konishiroku Photo Ind Co Ltd フエノ−ル系シアンカプラ−
DE3523705A1 (de) 1985-07-03 1987-01-08 Hoechst Ag Arzneimittel und deren verwendung
EP0253310A2 (fr) 1986-07-11 1988-01-20 E.I. Du Pont De Nemours And Company Imidazoles qui bloquent les récepteurs de l'angiotensine II
EP0324377A2 (fr) 1988-01-07 1989-07-19 E.I. Du Pont De Nemours And Company Imidazoles à activité bloquante de récepteur de l'angiotensine II et leurs combinaisons avec des agents diurétiques et NSaids
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
EP0347168A1 (fr) 1988-06-13 1989-12-20 Ono Pharmaceutical Co., Ltd. Dérivés d'ester phényl-p-substitués de l'acide pivalique
EP0420805A2 (fr) 1989-09-26 1991-04-03 Ciba-Geigy Ag Composés anthelmintiques
EP0420804A2 (fr) 1989-09-26 1991-04-03 Ciba-Geigy Ag Composés anthelmintiques
EP0449699A2 (fr) 1990-03-19 1991-10-02 Laboratoires Upsa Dérivés de pyrazole antagonistes des récepteurs à l'angiotensine II, leurs procédés de préparation, compositions pharmaceutiques les contenant
EP0530702A1 (fr) 1991-09-04 1993-03-10 MERCK PATENT GmbH Dihydro-1,2 oxo-2 pyridines comme antagonistes d'angiotensine II
WO1998027053A1 (fr) 1996-12-18 1998-06-25 Ono Pharmaceutical Co., Ltd. Derives de sulfamide et de carboxamide, et medicaments contenant ces derives en tant que principe actif
US6335334B1 (en) * 1998-07-08 2002-01-01 Aventis Pharma Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171352A (en) * 1875-12-21 Improvement in shirt-fronts
US61887A (en) * 1867-02-05 Improved gas appakatus
SU1766919A1 (ru) * 1990-12-13 1992-10-07 Ф.С.Михайлицын и Н.П.Козырева Способ получени N-(5,7-дибромбензо-2,1,3-тиадиазолил-4)-2-(4-хлорфенилсульфонамидо)-5-бромбензамида
US5447939A (en) * 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
JPH0959236A (ja) * 1995-08-23 1997-03-04 Dai Ichi Seiyaku Co Ltd ベンズアミド化合物
US5868159A (en) 1996-07-12 1999-02-09 Mks Instruments, Inc. Pressure-based mass flow controller
DE19830431A1 (de) * 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Sulfonylamino-carbonsäure-N-arylamide als Guanylatcyclase-Aktivatoren
AU2002213048A1 (en) * 2000-10-05 2002-04-15 Smith Kline Beecham Corporation Phosphate transport inhibitors
WO2004073634A2 (fr) * 2003-02-20 2004-09-02 Encysive Pharmaceuticals Inc. Antagonistes du recepteur de l'urotensine-ii de la phenylenediamine et antagonistes du ccr-9

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US994730A (en) * 1910-10-06 1911-06-13 Jesse M Evans Automatic funnel.
GB865735A (en) * 1957-12-24 1961-04-19 Geigy Ag J R Process for the production of new aminobenzoic acid derivatives and their use in pest control
FR1579473A (fr) 1966-10-21 1969-08-29
GB1198301A (en) 1966-10-21 1970-07-08 Minnesota Mining & Mfg Perfluoroalkylsulfonamides
JPS5916871A (ja) * 1982-07-20 1984-01-28 Shionogi & Co Ltd スルホンアミド系ベンズアミド類
JPS59162547A (ja) * 1983-03-07 1984-09-13 Konishiroku Photo Ind Co Ltd フエノ−ル系シアンカプラ−
DE3523705A1 (de) 1985-07-03 1987-01-08 Hoechst Ag Arzneimittel und deren verwendung
EP0253310A2 (fr) 1986-07-11 1988-01-20 E.I. Du Pont De Nemours And Company Imidazoles qui bloquent les récepteurs de l'angiotensine II
EP0324377A2 (fr) 1988-01-07 1989-07-19 E.I. Du Pont De Nemours And Company Imidazoles à activité bloquante de récepteur de l'angiotensine II et leurs combinaisons avec des agents diurétiques et NSaids
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
EP0347168A1 (fr) 1988-06-13 1989-12-20 Ono Pharmaceutical Co., Ltd. Dérivés d'ester phényl-p-substitués de l'acide pivalique
EP0420805A2 (fr) 1989-09-26 1991-04-03 Ciba-Geigy Ag Composés anthelmintiques
EP0420804A2 (fr) 1989-09-26 1991-04-03 Ciba-Geigy Ag Composés anthelmintiques
US5077300A (en) 1989-09-26 1991-12-31 Ciba-Geigy Corporation Anthelmintics
US5081125A (en) 1989-09-26 1992-01-14 Ciba-Geigy Corporation Anthelmintics
EP0449699A2 (fr) 1990-03-19 1991-10-02 Laboratoires Upsa Dérivés de pyrazole antagonistes des récepteurs à l'angiotensine II, leurs procédés de préparation, compositions pharmaceutiques les contenant
EP0530702A1 (fr) 1991-09-04 1993-03-10 MERCK PATENT GmbH Dihydro-1,2 oxo-2 pyridines comme antagonistes d'angiotensine II
WO1998027053A1 (fr) 1996-12-18 1998-06-25 Ono Pharmaceutical Co., Ltd. Derives de sulfamide et de carboxamide, et medicaments contenant ces derives en tant que principe actif
EP0947500A1 (fr) 1996-12-18 1999-10-06 Ono Pharmaceutical Co., Ltd. Derives de sulfamide et de carboxamide, et medicaments contenant ces derives en tant que principe actif
US6335334B1 (en) * 1998-07-08 2002-01-01 Aventis Pharma Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them

Non-Patent Citations (45)

* Cited by examiner, † Cited by third party
Title
A. M. El-Nagger et al., Synthesis and Biological Activity of Some New 4-(Aminoacyl)Aminopyridines and 2-(Aminoacyl)Aminopyrimidine Derivatives, Pol. J. Chem., 1982, pp. 1279-1285.
Alexander Mülsch et al., Purification of Heme-Containing Soluble Guanylyl Cyclase, Methods in Enzymology, vol. 195, 1991, pp. 377-383.
Boltin et al.;"Zh. Vses Khim. Obshchest.";13/4,475-6(1968).* *
Chemical Abstracts, vol. 100, Abstract No. 209 423.
Chemical Abstracts, vol. 102, Abstract No. 70 111.
Chemical Abstracts, vol. 104, Abstract 177 628.
Chemical Abstracts, vol. 104, Abstract No. 33 896.
Chemical Abstracts, vol. 106, Abstract No. 138 322.
Chemical Abstracts, vol. 106, Abstract No. 152 850.
Chemical Abstracts, vol. 115, Abstract No. 158 666.
Chemical Abstracts, vol. 116, Abstract No. 207 806.
Chemical Abstracts, vol. 116, Abstract No. 228 237.
Chemical Abstracts, vol. 116, Abstract No. 245 151.
Chemical Abstracts, vol. 117, Abstract No. 39 809.
Chemical Abstracts, vol. 119, Abstract No. 105 757.
Chemical Abstracts, vol. 119, Abstract No. 116 978.
Chemical Abstracts, vol. 119, Abstract No. 180 796.
Chemical Abstracts, vol. 120, Abstract No. 560.
Chemical Abstracts, vol. 122, Abstract No. 136 749.
Chemical Abstracts, vol. 126, Abstract No. 277 494.
Chemical Abstracts, vol. 70, Abstract No. 77 907.
Chemical Abstracts, vol. 74, Abstract No. 99 956.
Chemical Abstracts, vol. 76, Abstract No. 33 659.
Chemical Abstracts, vol. 77, Abstract No. 126 528.
Chemical Abstracts, vol. 77, Abstract No. 164 616.
Chemical Abstracts, vol. 79, Abstract No. 18 616.
Chemical Abstracts, vol. 81, Abstract No. 91 449.
Chemical Abstracts, vol. 99, Abstract No. 157 667.
Cheu M. Yu et al., Mechanism of Anti-proliferation Caused by YC-1, An Indazole Derivative, In Cultured Rat A10 Vascular Smooth-muscle Cells, Biochem J. (1995), 306, 767-792.
Chin-Chung Wu et al., YC-1 Inhibited Human Platelet Aggregation Through NO-independent Activation of Soluble Guanylate Cyclase, British Journal of Pharmacology (1995), 116, 1973-1978.
D. L. Vesley, B Complex Vitamins Activate Rat Guanylate Cyclase and Increase Cyclic GMP Levels, European Journal of Clinical Investigation, vol. 15, 1985, pp. 258-262.
David L. Vesely, Phencyclidine Stimulates Guanylate Cyclase Activity, Biochemical and Biophysical Research Communications, vol. 88, No. 4, Jun. 27, 1979, pp. 1244-1248.
Douglas J. Pettibone et al., A Structurally Novel Stimulator of Guanylate Cyclase With Long-Lasting Hypotensive Activity in the Dog, European Journal of Pharmacology, vol. 116, 1985, pp. 307-312.
Feng-Nien Ko et al., YC-1, A Novel Activator of Platelet Guanylate Cyclase, Blood, vol. 84, No. 12, Dec. 15, 1994, pp. 4226-4233.
Helen G. McFadden et al., Synthesis of Pyrazoles and Pyrazolo[1,5-alpha]pyrimidines from 3-Arylsulfonylaminoacrylates, Aust. J. Chem., vol. 46, 1993, pp. 873-886.
Helen G. McFadden et al., Synthesis of Pyrazoles and Pyrazolo[1,5-α]pyrimidines from 3-Arylsulfonylaminoacrylates, Aust. J. Chem., vol. 46, 1993, pp. 873-886.
John V. Duncia et al., The Discovery of Potent Nonpeptide Angiotensin II Receptor Antagonists: A New Class of Potent Antihypertensives, J. Med. Chem., 1990, vol. 33, pp. 1312-1329.
L. Gera et al., Sterochemical Studies, XXXII, Acid Amides of Potential Pharmacological Activity, IV, Acta Chim. Hung, 99 (2): 175-192 (1979).
Louis J. Ignarro, Regulation of Cytosolic Guanylyl Cyclase by Porphyrins and Metalloporphyrins, Advances in Pharmacology, vol. 26, 1994, pp. 35-64.
Mikhailitsyn et al.;"Med.Parazitol. Parazit. Bolezni"; 6, 52-3,(1991).* *
Morrison & Boyd;"Organic Chemistry", pp. 966-967 (1983).* *
Pancras C. Wong et al., Nonpeptide Angiotensin II Receptor Antagonists, Hypertension, vol. 15, No. 6, Part 2, Jun. 1990, pp. 823-834.
Sheu-Meei Yu et al., Vasorelaxant Effect of Isoliquiritigenin, A Novel Soluble Guanylate Cyclase Activator, In Rat Aorta, British Journal of Pharmacology (1995), 114, 1587-1594.
U.S. patent application Ser. No. 994,730, Urusla Schindler et al., filed Nov. 2001.* *
Yoshinori Tominaga et al., Synthesis of Quinoline Derivatives Using Ketene Dithioacetals, J. Heterocycl. Chem., vol. 27, 1990, pp. 1217-1225.

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106213B2 (en) 1998-07-08 2012-01-31 Sanofi-Aventis Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them
US6809089B2 (en) * 1998-07-08 2004-10-26 Aventis Pharma Deutschland Gmbh Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators
US20050080073A1 (en) * 1998-07-08 2005-04-14 Aventis Pharma Deutschland Gmbh Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators
US6881735B2 (en) 1998-07-08 2005-04-19 Aventis Pharma Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them
US20040186145A1 (en) * 1998-07-08 2004-09-23 Aventis Pharma Deutschland Gmbh. Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them
US7326789B2 (en) 1998-07-08 2008-02-05 Sanofi-Aventis Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them
US8541410B2 (en) 1998-07-08 2013-09-24 Sanofi-Aventis Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them
US7351703B2 (en) 1998-07-08 2008-04-01 Sanofi-Aventis Deutschland Gmbh Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators
US20080096936A1 (en) * 1998-07-08 2008-04-24 Ursula Schindler Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them
US20070015762A1 (en) * 1999-11-26 2007-01-18 Yasuyuki Kawanishi NPY Y5 antagonist
US7781461B2 (en) 1999-11-26 2010-08-24 Yasuyuki Kawanishi NPY Y5 antagonist
US20100292500A1 (en) * 1999-11-26 2010-11-18 Yasuyuki Kawanishi Npy y5 antagonist
US20110039802A1 (en) * 1999-11-26 2011-02-17 Yasuyuki Kawanishi Npy y5 antagonist
US8115027B2 (en) 1999-11-26 2012-02-14 Shionogi & Co., Ltd. NPY Y5 antagonist
US7468369B2 (en) 2005-01-04 2008-12-23 Sanofi-Aventis Sulfonyl pyrrolidines, method for producing the same and their use as drugs
US20080045540A1 (en) * 2005-01-04 2008-02-21 Sanofi-Aventis Deutschland Gmbh Sulfonyl pyrrolidines, method for producing the same and their use as drugs
US20090021075A1 (en) * 2007-07-20 2009-01-22 Nec Electronics Corporation Semiconductor device

Also Published As

Publication number Publication date
WO2000002850A2 (fr) 2000-01-20
US6809089B2 (en) 2004-10-26
ATE296800T1 (de) 2005-06-15
CA2336702C (fr) 2010-03-09
CA2336702A1 (fr) 2000-01-20
EP1095015A2 (fr) 2001-05-02
BR9911942B1 (pt) 2013-12-10
KR20010053437A (ko) 2001-06-25
AR019231A1 (es) 2001-12-26
JP4422335B2 (ja) 2010-02-24
JP2002520308A (ja) 2002-07-09
EP1095015B1 (fr) 2005-06-01
US7351703B2 (en) 2008-04-01
ES2242407T3 (es) 2005-11-01
US20050080073A1 (en) 2005-04-14
US20030171352A1 (en) 2003-09-11
PT1095015E (pt) 2005-09-30
KR101021042B1 (ko) 2011-03-14
AU5155399A (en) 2000-02-01
BR9911942A (pt) 2001-03-27
DE59912117D1 (de) 2005-07-07
DK1095015T3 (da) 2005-09-12
DE19830431A1 (de) 2000-01-13
WO2000002850A3 (fr) 2000-04-13

Similar Documents

Publication Publication Date Title
KR100720844B1 (ko) 황 치환된 설포닐아미노카복실산 ｎ-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제
RU2234497C2 (ru) Серозамещенные n-ариламиды сульфониламинокарбоновой кислоты, способ их получения (варианты), фармацевтическая композиция и способ лечения
AU760988B2 (en) Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same
JP4695262B2 (ja) 置換４−アミノ−２−アリールシクロペンタ［ｄ］ピリミジン、それらの製造、それらの使用およびそれらを含有する医薬製剤
US6548547B1 (en) Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators
US7045526B2 (en) Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them
MXPA00012966A (es) N-arilamidas de acido sulfonilaminocarboxilico con sustitucion de azufre, su preparacion, su uso y preparaciones farmaceuticas que las contienen
DE19903126A1 (de) Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Legal Events

Date Code Title Description
AS Assignment

Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHINDLER, URSULA;SCHOENAFINGER, KARL;STROBEL, HARTMUT;REEL/FRAME:011581/0387;SIGNING DATES FROM 20001127 TO 20001130

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:016793/0789

Effective date: 20050901

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH,GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:016793/0789

Effective date: 20050901

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12